Shareholders Foundation, Inc.

An investigation for investors in AngioDynamics, Inc. (NASDAQ:ANGO) shares over potential securities laws violations by AngioDynamics, Inc. was announced and NASDAQ:ANGO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

San Diego, CA -- (SBWIRE) -- 04/20/2015 -- An investigation on behalf of investors of AngioDynamics, Inc. (NASDAQ:ANGO) shares over potential securities laws violations by AngioDynamics, Inc. and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of AngioDynamics, Inc. (NASDAQ:ANGO) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of AngioDynamics, Inc. (NASDAQ:ANGO) concerning whether a series of statements by AngioDynamics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

AngioDynamics, Inc. reported that its Total Revenue rose from $221.92 million for the 52 weeks period that ended on May 31, 2012 to $354.43 million for the 52 weeks period that ended on May 31, 2014, and that its Net loss of $5.18 million for the 52 weeks period that ended on May 31, 2012 turned into a Net Income of $2.67 million for the 52 weeks period that ended on May 31, 2014. Shares of AngioDynamics, Inc. (NASDAQ:ANGO) grew to as high as $19.72 per share in late January 2015.

On April 9, 2015, AngioDynamics, Inc. reported its 2015 third quarter financial results.

Among other things, AngioDynamics, Inc said that its third quarter net sales of $86.6 million decreased 2% year over year from $88.2 million in last fiscal year's third quarter. AngioDynamics, Inc also provided its fiscal 2015 and fourth quarter guidance. AngioDynamics, Inc said that its short term impact coupled with the headwinds due to foreign currency exchange has resulted in a revision of net sales for fiscal year 2015 to a range of $356 million to $360 million from its prior outlook of a range of $362 million to $368 million.

Shares of Shares of AngioDynamics, Inc. (NASDAQ:ANGO) declined on April 10, 2015 to as low as $16.25 per share.